The Tariff Is Now a Veto Over Domestic Law

The specific authorities this administration is using have changed, but the trade strategy has not. — Jamieson Greer

Between March and July of 2026, the Trump administration launched Section 301 trade investigations across five unrelated sovereign policy domains. Forced labor, covering 60 economies, with a probe launched March 12 ^[1]. Industrial overcapacity, covering 16 economies, with a probe launched within 24 hours of the forced-labor action ^[2]. Intellectual property enforcement in Vietnam, announced May 29 ^[3]. Pharmaceutical pricing in Germany, launched June 18 ^[4]. And on July 24, hours after the European Union fined Google $1 billion under the Digital Markets Act, a Section 301 investigation into the EU itself ^[5]. Stacked on top of all of it is a Section 232 national-security tariff on pharmaceuticals, imposed in April ^[6]. The legal theory changes with each target. The demand does not: change your domestic law or face tariffs. Vietnam is where the pattern becomes unmistakable. The country currently faces three concurrent Section 301 investigations — forced labor, intellectual property enforcement, and excess manufacturing capacity — three different legal theories running against the same target at the same time ^[3]. The IP probe, launched in late May, was the third opened against Vietnam this year. The administration had already designated Vietnam a Priority Foreign Country for the first time in 13 years, and the response was immediate: Deputy Prime Minister Ho Quoc Dung mandated a 20 percent increase in IP case detection, piracy website takedowns, and customs suspensions ^[7]. The probes are not diagnosing distinct problems. They are interchangeable levers, and Vietnam is the clearest proof. The mechanism that makes the lever work is visible in Sri Lanka. The country still faced the maximum 12.5 percent tariff rate despite what its own deputy minister acknowledged ^[8].

Sri Lanka already has good labour practices within the country. — Anil Jayantha Fernando

To drop to the 10 percent tier, Sri Lanka amended its customs laws and adopted an International Labour Organization convention it had not previously ratified ^[8]. The tariff did not correct a labor abuse. It extracted a legislative concession, and the rate fell. From labor law, the instrument jumped to healthcare. The Germany probe, launched in June, demands that the German government raise pharmaceutical prices to benefit American drug companies. The legal theory the USTR invoked has nothing to do with forced labor, overcapacity, or intellectual property ^[4].

Germany should follow suit with constructive negotiations to address this imbalance. — Jamieson Greer

It is a demand that a sovereign government change how it sets healthcare prices to benefit American pharmaceutical companies. The Section 232 pharma tariff, imposed in April under a national-security rationale, runs on a parallel track: companies can reduce the 100 percent rate to 20 percent by committing to build US plants, or to zero through pricing agreements ^[6]. Two different statutes, the same demand. Then came the EU antitrust case, and the instrument crossed a categorical line. On July 23, the European Commission fined Google $1 billion for violating the Digital Markets Act. Within hours, Trump launched a Section 301 investigation into the EU ^[5].

We will immediately initiate a 301 Investigation into the practice of "ROBBING" American Companies. — Donald Trump

This is not a trade dispute. The EU fined an American company under a competition law that applies equally to European firms. The Section 301 tariff — originally designed to address unfair foreign trade practices — is now being deployed to veto a foreign regulatory penalty against a US corporation. The domain is no longer labor standards, manufacturing capacity, intellectual property, or even drug pricing. It is the enforcement of domestic competition law against an American company. The tariff has become a universal objection to any foreign legislation that affects US commercial interests. The administration's own stated beneficiaries have noticed the cost. The National Council of Textile Organizations fought for the forced-labor tariff, expecting it to protect domestic manufacturers. Instead, the administration carved out exemptions for Bangladesh, Cambodia, Indonesia, and Malaysia — countries whose compliance serves diplomatic leverage. NCTO president Kim Glas put it plainly ^[9].

We remain strongly concerned that USTR’s textile mechanism will harm the very domestic manufacturers the administration seeks to help. — Kim Glas

The exemptions are not an accident. The US-Bangladesh trade deal, signed in February, conditioned zero-tariff textile quotas on Bangladesh purchasing American-made cotton and inputs — a commercial arrangement that has nothing to do with forced labor ^[10]. When diplomatic or commercial leverage requires an exemption, the domestic manufacturer the tariff was sold to protect becomes expendable. The instrument now operates on its own logic. It began as a labor-compliance tool, expanded into a reshoring mechanism, and has now reached the point where it is used to shield a single American company from a foreign antitrust penalty. The EU case is not an extension of the pattern. It is a break. A trade weapon has been aimed at the enforcement of a foreign competition law, and the demand is the same as it was for Sri Lanka's labor code and Germany's drug prices: change your law, or pay.